Status:
COMPLETED
Investigating the Pharmacokinetic Drug Interactions Between HGP1201 and HGP0904
Lead Sponsor:
Hanmi Pharmaceutical Company Limited
Conditions:
Healthy
Eligibility:
MALE
19-45 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to investigate the pharmacokinetic drug interactions between HGP1201 and HGP0904
Detailed Description
Randomized, open-label, multiple dose , 3-treatment, 6-sequence, 3-period, crossover study, The purpose of this study is to investigate the pharmacokinetic drug interactions between HGP1201 and HGP090...
Eligibility Criteria
Inclusion
- Healthy male volunteer, age 19\~45 years
- The result of Body Mass Index(BMI) is not less than 19 kg/m2 , no more than 28 kg/m2
- Subject who has the ability to comprehend the study objectives, contents and the property of the study drug before participating in the trial.
Exclusion
- Presence of medical history or a concurrent disease that may interfere with treatment and safety assessment or completion of this clinical study
- History of relevant drug allergies or clinically significant hypersensitivity reaction.
Key Trial Info
Start Date :
September 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2014
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT02243319
Start Date
September 1 2014
End Date
December 1 2014
Last Update
October 20 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Asan Medical Center
Seoul, South Korea